CERVOMED INC (CRVO)
(Delayed Data from NSDQ)
$13.75 USD
+0.25 (1.85%)
Updated Oct 14, 2024 04:00 PM ET
After-Market: $13.75 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
CRVO 13.75 +0.25(1.85%)
Will CRVO be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for CRVO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CRVO
CERVOMED INC (CRVO) Soars 10.6%: Is Further Upside Left in the Stock?
CRVO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for CRVO
CervoMed files for $250M mixed securities shelf
CervoMed files $250M mixed securities shelf
CervoMed Ends $20 Million Stock Sales Agreement with BTIG
CervoMed to Deliver Late-Breaking Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)
CervoMed to present on neflamapimod as DLB treatment at CTAD